MUC1 and non-small cell lung carcinoma: Furthermore, the tumor antigens could be modified to fuse or mix with cytokines, antibodies, or immunogenic peptides in the protein/peptide-based cancer vaccines, e.g., Oncophage for kidney cancer, melanoma, and brain cancer and Stimuvax (BLP25 liposome vaccine) targeting MUC1 for NSCLC and breast cancer [34, 62, 63].